- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

SMC accepts AbbVie’s new Parkinson’s drug within NHS Scotland

The Scottish Medicines Consortium (SMC) has accepted AbbVie’s new Produodopa® (foslevodopa-foscarbidopa) for restricted use within NHS Scotland for the treatment of advanced levodopa-responsive Parkinson’s disease.

The SMC has restricted its use to patients with advanced Parkinson’s disease who are not eligible for deep brain stimulation (DBS).

Foslevodopa-foscarbidopa offers an additional treatment choice in the therapeutic class of dopa and dopaderivatives for this indication. Another medicine within this therapeutic class has been accepted via the orphan medicine process for this indication. This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.1

There are approximately 153,000 people with Parkinson’s disease across the UK and 12,400 of these live in Scotland, with about 30 people diagnosed with this progressive and chronic condition every week.2,3

Foslevodopa-foscarbidopa is a new, soluble formulation of levodopa/carbidopa prodrugs, which can be self-administered by continuous subcutaneous infusion via a pump 24-hours a day. It has been developed to provide another therapeutic option for eligible patients with advanced levodopa-responsive Parkinson’s disease.4

Parkinson’s disease is frequently talked about in terms of “On” and “Off” time. “On” time refers to when symptoms are controlled, while “Off” time is when Parkinson’s disease symptoms – motor and/or non-motor – return between medication doses or may occur unpredictably.5,6

Rachael Millward, Medical Director, AbbVie UK said: “The SMC’s decision to make this treatment available on the NHS in Scotland means that eligible patients across the UK will now be able to access this treatment option. AbbVie is committed to transforming the standards of care in Parkinson’s disease and delivering therapies to support patients and caregivers at the beginning and throughout their treatment journey.”

References:

1 SMC. Foslevodopa-foscarbidopa (Produodopa). Available from: https://www.scottishmedicines.org.uk/medicinesadvice/foslevodopa-foscarbidopa-produodopa-abb-smc2574/ [Last accessed: March 2024]

2 Parkinson’s UK. What is Parkinson’s? Available from: https://www.parkinsons.org.uk/information-and-support/whatparkinsons [Last Accessed: March 2024]

3 The Scottish Parliament Citizen Participation and Public Petitions Committee. Parkinson’s UK Scotland submission of 3 September 2021. Available from: https://www.parliament.scot/chamber-and-committees/committees/current-and-previous-committees/session-6-citizen-participation-and-public-petitions-committee/correspondence/2021/pe1854_c-parkinsons-uk-scotland-submission-of-3-september-2021# [Last Accessed: March 2024]

4 PRODUODOPA® (foslevodopa-foscarbidopa) GB Summary of Product Characteristics. Available at:
https://www.medicines.org.uk/emc/product/15213/smpc#about-medicine. [Last Accessed: March 2024]

5 Parkinson’s Europe. Wearing off and motor fluctuations. Available from: https://www.parkinsonseurope.org/aboutparkinsons/symptoms/motor-symptoms/wearing-off-and-motor-fluctuations/ [Last Accessed: March 2024]

6 The Michael J. Fox Foundation. “Off” Time in Parkinson’s Disease. Available at: https://www.michaeljfox.org/timeparkinsons-disease [Last Accessed: March 2024]

- Advertisement -
Joanna Harvey
Joanna Harvey
Marketing and Communication Executive | Uniphar Commercial

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription